Nilgün Karabıçak
Research Subjects
Nilgün Karabıçak has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ayşe Nur Ceylan
Istanbul Basaksehir Cam and Sakura City Hospital, Medical Microbiology Laboratory, Istanbul, Turkey
2 shared publications - Selda Kömeç
Istanbul Başakşehir Çam and Sakura City Hospital
2 shared publications - Abdurrahman Gülmez
Istanbul Basaksehir Cam and Sakura City Hospital, Medical Microbiology Laboratory, Istanbul, Turkey
1 shared publication - Aliye Bastug
University of Health Sciences, Ankara Bilkent City Hospital
1 shared publication - Aysegul Ulu-Kilic
Department of Infectious Diseases and Clinical Microbiology, Erciyes University, Kayseri, Türkiye
1 shared publication - Ayşe Kalkancı
Department of Medical Microbiology, Faculty of Medicine, Gazi University, Ankara, Turkiye
1 shared publication
Latest Publications
- Open Access
- 5 November 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (11) , 830
Evaluation of the Zybio EXS2600 Mass Spectrometry for Accurate and Fast Identification of Filamentous Fungi Clinical Isolates
Aim: This study evaluated the performance of the new Zybio EXS2600 Ex-Accuspec database and system in identifying clinical filamentous fungal pathogens, comparing it with the existing Bruker Filamentous Fungi Library 3.0 database and system. Background: Delayed and inaccurate diagnoses can significantly increase the risk of mortality associated with invasive mold infections. Recently, the identification of mold isolates using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) has progressed beyond traditional morphological identification methods. Method: A total of 180 well-characterized clinical mold isolates, representing 23 species across 11 genera, were analyzed alongside eight reference strains from three genera. This analysis was conducted using the direct extraction method on both the EXS2600 and the Biotyper. The results were evaluated using both the manufacturer-recommended cutoff scores and lower cutoff scores. Result: Among the 180 clinical isolates, the EXS2600 achieved significantly higher identification rates than the Bruker Biotyper at both the species/species-complex level (57.2% vs. 17.2%) and genus level (82.8% vs. 45.6%) using the manufacturer-recommended score thresholds (both p < 0.001). When reduced score thresholds were applied, identification rates increased to 82.8% and 91.7% at the species/species-complex and genus levels, respectively, for the EXS2600, compared with 45.6% and 66.7% for the Bruker Biotyper (both p < 0.001). The EXS2600 system achieved high species-level identification rates for Aspergillus fumigatus (80.8%), Aspergillus flavus (93.8%), and dermatophytes (85.0%). In contrast, the Bruker Biotyper showed numerically higher species/species-complex-level identification rates for the Fusarium solani species complex (28.6%) and the Fusarium fujikuroi species complex (28.6%) compared with the EXS2600. Both systems showed limited identification performance for dematiaceous molds, while Trichophyton indotineae was not represented in the Bruker Biotyper database. Additionally, the EXS2600 offered a simpler sample preparation workflow compared with the Biotyper. Conclusions: Our results highlight the Zybio EXS2600 Ex-Accuspec database and system as a promising and reliable tool for the routine identification of filamentous fungi, demonstrating high identification rates and a relatively simple sample preparation procedure. Additionally, lowering the validity cutoff levels may improve the Zybio EXS2600 system’s performance.
- 5 November 2026
- Published by MDPI AG in Journal of Fungi
- Vol. 12 (11) , 830
Open AccessEvaluation of the Zybio EXS2600 Mass Spectrometry for Accurate and Fast Identification of Filamentous Fungi Clinical Isolates
Aim: This study evaluated the performance of the new Zybio EXS2600 Ex-Accuspec database and system in identifying clinical filamentous fungal pathogens, comparing it with the existing Bruker Filamentous Fungi Library 3.0 database and system. Background: Delayed and inaccurate diagnoses can significantly increase the risk of mortality associated with invasive mold infections. Recently, the identification of mold isolates using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (MALDI-TOF MS) has progressed beyond traditional morphological identification methods. Method: A total of 180 well-characterized clinical mold isolates, representing 23 species across 11 genera, were analyzed alongside eight reference strains from three genera. This analysis was conducted using the direct extraction method on both the EXS2600 and the Biotyper. The results were evaluated using both the manufacturer-recommended cutoff scores and lower cutoff scores. Result: Among the 180 clinical isolates, the EXS2600 achieved significantly higher identification rates than the Bruker Biotyper at both the species/species-complex level (57.2% vs. 17.2%) and genus level (82.8% vs. 45.6%) using the manufacturer-recommended score thresholds (both p < 0.001). When reduced score thresholds were applied, identification rates increased to 82.8% and 91.7% at the species/species-complex and genus levels, respectively, for the EXS2600, compared with 45.6% and 66.7% for the Bruker Biotyper (both p < 0.001). The EXS2600 system achieved high species-level identification rates for Aspergillus fumigatus (80.8%), Aspergillus flavus (93.8%), and dermatophytes (85.0%). In contrast, the Bruker Biotyper showed numerically higher species/species-complex-level identification rates for the Fusarium solani species complex (28.6%) and the Fusarium fujikuroi species complex (28.6%) compared with the EXS2600. Both systems showed limited identification performance for dematiaceous molds, while Trichophyton indotineae was not represented in the Bruker Biotyper database. Additionally, the EXS2600 offered a simpler sample preparation workflow compared with the Biotyper. Conclusions: Our results highlight the Zybio EXS2600 Ex-Accuspec database and system as a promising and reliable tool for the routine identification of filamentous fungi, demonstrating high identification rates and a relatively simple sample preparation procedure. Additionally, lowering the validity cutoff levels may improve the Zybio EXS2600 system’s performance.
- Open Access
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 1039-1062
Consensus paper on Candida auris by Türkiye EKMUD, THSK of Ministry of Health of the Republic of Türkiye, KLIMUD, TMC, TARD, TYBD and ID-IRI
Candida auris is an emerging fungal pathogen that has become a critical global health concern due to its high antifungal resistance and potential to cause nosocomial outbreaks. Since its initial identification in Japan in 2009, C. auris has spread rapidly, posing significant treatment challenges across various healthcare settings worldwide. The biofilm formation ability of C. auris enhances its resilience against disinfectants and antifungal agents, complicating infection control in healthcare environments. This consensus report, developed with the collaboration of several Turkish medical specialty societies, including the Turkish Society of Infectious Diseases and Clinical Microbiology Specialty (EKMUD), the Turkish Society of Anesthesiology and Reanimation (TARD), the Turkish Intensive Care Society (TYBD), the Infectious Diseases – International Research Initiative (ID-IRI), the Clinical Microbiology Specialist Society (KLIMUD), the Turkish Microbiology Society (TMC), and the Public Health Institution of Türkiye (PHIT) under the Ministry of Health, provides a comprehensive overview of C. auris and its’ management. The report focuses on the epidemiology, antifungal resistance mechanisms, recommendations for diagnostic and therapeutic challenges, infection control and prevention measures and surveillance of C. auris. This consensus report aims to establish standardized diagnostic protocols, improve national surveillance systems, and promote effective infection control measures to mitigate C. auris related health risks in Türkiye. It also offers comprehensive national recommendations and addresses the need for inter-institutional collaboration, improve public health, and strengthen the healthcare response to this pathogens.
- 15 August 2025
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 55 (4) , 1039-1062
Open AccessConsensus paper on Candida auris by Türkiye EKMUD, THSK of Ministry of Health of the Republic of Türkiye, KLIMUD, TMC, TARD, TYBD and ID-IRI
Candida auris is an emerging fungal pathogen that has become a critical global health concern due to its high antifungal resistance and potential to cause nosocomial outbreaks. Since its initial identification in Japan in 2009, C. auris has spread rapidly, posing significant treatment challenges across various healthcare settings worldwide. The biofilm formation ability of C. auris enhances its resilience against disinfectants and antifungal agents, complicating infection control in healthcare environments. This consensus report, developed with the collaboration of several Turkish medical specialty societies, including the Turkish Society of Infectious Diseases and Clinical Microbiology Specialty (EKMUD), the Turkish Society of Anesthesiology and Reanimation (TARD), the Turkish Intensive Care Society (TYBD), the Infectious Diseases – International Research Initiative (ID-IRI), the Clinical Microbiology Specialist Society (KLIMUD), the Turkish Microbiology Society (TMC), and the Public Health Institution of Türkiye (PHIT) under the Ministry of Health, provides a comprehensive overview of C. auris and its’ management. The report focuses on the epidemiology, antifungal resistance mechanisms, recommendations for diagnostic and therapeutic challenges, infection control and prevention measures and surveillance of C. auris. This consensus report aims to establish standardized diagnostic protocols, improve national surveillance systems, and promote effective infection control measures to mitigate C. auris related health risks in Türkiye. It also offers comprehensive national recommendations and addresses the need for inter-institutional collaboration, improve public health, and strengthen the healthcare response to this pathogens.
- Open Access
- 29 July 2025
- Published by MediHealth Academy in Ankyra Medical Journal
- Vol. 4 (3) , 58-61
A case developing Candida auris related candidaemia following multiple drug-resistant Klebsiella pneumoniae meningitis after neurosurgical intervention
A 28-year-old man who underwent ventriculoperitoneal shunt (VPS) operation at another medical center due to epidural abscess and hydrocephalus was admitted due to deterioration of his general condition. WBC count was 9360/mm³, C-reactive protein (CRP) was 54 mg/L (normal range <5 mg/L) and glomerular filtration rate was 150 ml/min, while the results of other laboratory tests were nonspecific. He was receiving vancomycin and meropenem treatment. Urine cultures were taken during hospitalization and again 48 hours later and Candida auris (C. auris) growth of 105 cfu/ml was detected. On the 4th day of hospitalization, the patient was intubated due to decreased oxygen saturation, and while under meropenem and vancomycin treatment, carbapenem-resistant, gentamicin and ceftazidime-avibactam-susceptible and multidrug-resistant Klebsiella pneumoniae growth was detected in CSF culture. The patient's ventriculoperitoneal shunt was removed and hydrocephalus was followed with extra-ventricular drainage (EVD). Vancomycin treatment was discontinued and intrathecal (IT) gentamicin treatment was started. Due to the susceptibility of Klebsiella pneumoniae growth from deep tracheal aspirate to ceftazidime-avibactam, antibiotic treatment was changed to intravenous (IV) meropenem, IV ceftazidime-avibactam and IT gentamicin and treatment was continued for 10 days. No growth was detected in CSF culture obtained under treatment. On the 20th day of hospitalization due to deterioration of his clinical condition under treatment, tracheostomy was performed, he was intubated, blood and urine cultures were repeated and C. auris growth was detected in blood culture on the 27th day after hospitalization using VITEK MS MALDITOF (bioMérieux, France) microbiological identification system. Confirmation of the C. auris species and antifungal susceptibility testing was performed by the Mycology Reference Laboratory, Institute of Public Health and antibiotic treatment was stopped. According to the antifungal susceptibility test results, the patient was started on anidulafungin. In conclusion, nosocomial C. auris infection should be considered in patients with underlying predisposing factors such as long intensive care unit stays, broad-spectrum antibiotic use, surgical interventions, central venous catheter use, intubation and infection due to gram-negative bacteria.
- 29 July 2025
- Published by MediHealth Academy in Ankyra Medical Journal
- Vol. 4 (3) , 58-61
Open AccessA case developing Candida auris related candidaemia following multiple drug-resistant Klebsiella pneumoniae meningitis after neurosurgical intervention
A 28-year-old man who underwent ventriculoperitoneal shunt (VPS) operation at another medical center due to epidural abscess and hydrocephalus was admitted due to deterioration of his general condition. WBC count was 9360/mm³, C-reactive protein (CRP) was 54 mg/L (normal range <5 mg/L) and glomerular filtration rate was 150 ml/min, while the results of other laboratory tests were nonspecific. He was receiving vancomycin and meropenem treatment. Urine cultures were taken during hospitalization and again 48 hours later and Candida auris (C. auris) growth of 105 cfu/ml was detected. On the 4th day of hospitalization, the patient was intubated due to decreased oxygen saturation, and while under meropenem and vancomycin treatment, carbapenem-resistant, gentamicin and ceftazidime-avibactam-susceptible and multidrug-resistant Klebsiella pneumoniae growth was detected in CSF culture. The patient's ventriculoperitoneal shunt was removed and hydrocephalus was followed with extra-ventricular drainage (EVD). Vancomycin treatment was discontinued and intrathecal (IT) gentamicin treatment was started. Due to the susceptibility of Klebsiella pneumoniae growth from deep tracheal aspirate to ceftazidime-avibactam, antibiotic treatment was changed to intravenous (IV) meropenem, IV ceftazidime-avibactam and IT gentamicin and treatment was continued for 10 days. No growth was detected in CSF culture obtained under treatment. On the 20th day of hospitalization due to deterioration of his clinical condition under treatment, tracheostomy was performed, he was intubated, blood and urine cultures were repeated and C. auris growth was detected in blood culture on the 27th day after hospitalization using VITEK MS MALDITOF (bioMérieux, France) microbiological identification system. Confirmation of the C. auris species and antifungal susceptibility testing was performed by the Mycology Reference Laboratory, Institute of Public Health and antibiotic treatment was stopped. According to the antifungal susceptibility test results, the patient was started on anidulafungin. In conclusion, nosocomial C. auris infection should be considered in patients with underlying predisposing factors such as long intensive care unit stays, broad-spectrum antibiotic use, surgical interventions, central venous catheter use, intubation and infection due to gram-negative bacteria.
- 16 July 2021
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 55 (3) , 452-460
Three Candida auris Case Reports from Istanbul, Turkey
Candida auris is a fungal pathogen that was first identified in 2009. Since its definition, it has spread globally and has caused life-threatening nosocomial infections. Increases in the number of immunocompromised individuals, empirical use of broad-spectrum antimicrobials and widespread use of catheterizations are the predisposing factors in the development of infection. There are problems for the identification of C.auris with the routine methods. In this case report, infections with C.auris, isolated for the first time from three patients in our hospital's intensive care units (ICU) between November 2020-January 2021, were presented. The first case was a 46-year-old male patient with laryngeal carcinoma who developed cardiopulmonary arrest during anesthesia induction in the tumor operation, and was followed up in the ICU. C.auris growth was detected in the blood and intravenous (IV) catheter tip cultures on the 66th day of admittance. Cure achieved on the 24th day under caspofungin treatment as no growth was determined. Second case was a 71-year-old female patient admitted to the emergency department with shortness of breath and general condition disorder that developed after COVID-19 infection and hospitalized in ICU with the diagnosis of pneumonia and acute renal failure. In the 16th day of admittance C.auris growth was detected in blood and from catheter tip cultures and the patient died in the 18th day. The third case was a 49-year-old male patient, followed up in ICU with the diagnosis of subarachnoid hemorrhage after he admitted to the emergency department with confusion. In the 35th day of admittance, 100000 CFU/ mL C auris growth was detected in urine culture. The patient was accepted as asymptomatic fungiuria and followed up in the ICU. It was determined that the three patients were intubated, had urinary and femoral venous catheters and were being followed under wide spectrum antibiotherapy when the growth of C.auris was detected. Isolates identified as C.auris by MALDI-TOF Microflex LT/SH Smart MS in the Medical Microbiology Laboratory were then confirmed by conventional methods and DNA sequencing in the National Mycology Reference Laboratory. Antifungal susceptibility tests were performed by broth microdilution method. Fluconazole MIC values were >256 mg/ml for all cases. Long-term survival in hospital environments, colonization on skin, resistance to disinfectants of C.auris, facilitate the spread of the fungi and resistance to antifungals lead to treatment failures. In this case report, it was aimed to draw attention to the infections with C.auris, its diagnosis and risk factors.
- 16 July 2021
- Published by Bilimsel Tip Publishing House in Mikrobiyoloji Bulteni
- Vol. 55 (3) , 452-460
Three Candida auris Case Reports from Istanbul, Turkey
Candida auris is a fungal pathogen that was first identified in 2009. Since its definition, it has spread globally and has caused life-threatening nosocomial infections. Increases in the number of immunocompromised individuals, empirical use of broad-spectrum antimicrobials and widespread use of catheterizations are the predisposing factors in the development of infection. There are problems for the identification of C.auris with the routine methods. In this case report, infections with C.auris, isolated for the first time from three patients in our hospital's intensive care units (ICU) between November 2020-January 2021, were presented. The first case was a 46-year-old male patient with laryngeal carcinoma who developed cardiopulmonary arrest during anesthesia induction in the tumor operation, and was followed up in the ICU. C.auris growth was detected in the blood and intravenous (IV) catheter tip cultures on the 66th day of admittance. Cure achieved on the 24th day under caspofungin treatment as no growth was determined. Second case was a 71-year-old female patient admitted to the emergency department with shortness of breath and general condition disorder that developed after COVID-19 infection and hospitalized in ICU with the diagnosis of pneumonia and acute renal failure. In the 16th day of admittance C.auris growth was detected in blood and from catheter tip cultures and the patient died in the 18th day. The third case was a 49-year-old male patient, followed up in ICU with the diagnosis of subarachnoid hemorrhage after he admitted to the emergency department with confusion. In the 35th day of admittance, 100000 CFU/ mL C auris growth was detected in urine culture. The patient was accepted as asymptomatic fungiuria and followed up in the ICU. It was determined that the three patients were intubated, had urinary and femoral venous catheters and were being followed under wide spectrum antibiotherapy when the growth of C.auris was detected. Isolates identified as C.auris by MALDI-TOF Microflex LT/SH Smart MS in the Medical Microbiology Laboratory were then confirmed by conventional methods and DNA sequencing in the National Mycology Reference Laboratory. Antifungal susceptibility tests were performed by broth microdilution method. Fluconazole MIC values were >256 mg/ml for all cases. Long-term survival in hospital environments, colonization on skin, resistance to disinfectants of C.auris, facilitate the spread of the fungi and resistance to antifungals lead to treatment failures. In this case report, it was aimed to draw attention to the infections with C.auris, its diagnosis and risk factors.